Key result
Clopidogrel is a useful, evidence-based antiplatelet agent that serves as an alternative to aspirin, particularly for patients with aspirin intolerance or peripheral arterial disease.
Why the study?
Is clopidogrel an effective antiplatelet agent for vascular disease prevention, particularly in patients with aspirin intolerance or peripheral arterial disease?
Is clopidogrel an effective antiplatelet agent for vascular disease prevention, particularly in patients with aspirin intolerance or peripheral arterial disease?
Answers are grounded in this paper and cite their sources.
This editorial highlights clopidogrel as a valuable evidence-based antiplatelet alternative to aspirin, with potential specific benefits in peripheral arterial disease.
In this editorial we consider some aspects of the use of clopidogrel in current clinical practice. Clopidogrel has replaced ticlopidine as an alternative to aspirin. Among the problems with the use of antiplatelet agents is aspirin intolerance. The options for these patients are discussed; these include using clopidogrel. Clopidogrel may be especially effective in patients with peripheral arterial disease. However, this impression requires confirmation in appropriately designed trials. We also consider the effect of antiplatelet agents on growth factor release by platelets and of clopidogrel on the inflammatory process. Clopidogrel is a useful, evidence-based, antiplatelet agent.
No takes yet. Share an insight, caveat, or question.
Daskalopoulou et al. (2004) conducted an editorial in Vascular disease. Clopidogrel vs. Aspirin was evaluated. Clopidogrel is a useful, evidence-based antiplatelet agent that serves as an alternative to aspirin, particularly for patients with aspirin intolerance or peripheral arterial disease.
Synapse has enriched 10 related papers. Consider them for comparative context: